Toll-like receptor 2-agonistic lipopeptides typified by S- [2, -propyl]-Rcysteinyl-S-serine (PAM 2 CS) compounds are potential vaccine adjuvants. We had previously determined that at least one acyl group of optimal length (C 16 ) and an appropriately orientated ester carbonyl group is essential for TLR2-agonistic activity. We now show that these structurally simpler analogues display agonistic activities with human, but not murine TLR2. SAR studies on the monoacyl derivatives show that the optimal acyl chain length is C 16 , and aryl substituents are not tolerated. A variety of alkyl and acyl substituents on the cysteine amine were examined. All Nalkyl derivatives were inactive. In contradistinction, short-chain N-acyl analogues were found to be highly active, with a clear dependence on the chain length. A cysteine N-acetyl analogue was found to be the most potent (EC 50 : 1 nM), followed by the N-butyryl analogue. The N-acetyl analogue is human TLR2-specific, with its potency comparable to that of PAM 2 CS.
Introduction
Vaccines are perhaps one of the most successful medical interventions against infectious disease. 1 An important component in the design of effective vaccines is the incorporation of appropriate immune potentiators (also termed adjuvants), along with the antigen; adjuvants initiate early innate immune responses which lead to the induction of robust and long-lasting adaptive immune responses. 2 More than eight decades have elapsed since the discovery of adjuvanticity of aluminum salts (primarily phosphate and hydroxide) by Glenny and coworkers, 3 and the repertoire of investigational adjuvants has grown to encompass a very wide range of materials; 4 however, aluminum salt-based mineral salts (generically, and incorrectly, termed "alum") have, until the recent introduction of 3-O-desacyl-4'-monophosphoryl lipid A (MPL), 5 remained the only adjuvants currently approved by the FDA. Aluminum salts have enjoyed a good safety record, but are weak adjuvants for antibody induction, promoting a T H 2-skewed, rather than a T H 1 response. 6, 7 Furthermore, not only are aluminum salts ineffective at inducing cytotoxic T lymphocyte (CTL) or mucosal IgA antibody responses, but also have an undesirable propensity to induce IgE isotype switching, which has been associated with allergic reactions in some subjects. 6, 7 Toll-like receptors (TLRs) are pattern recognition receptors present on diverse cell types. TLRs recognize specific molecular patterns present in molecules that are broadly shared by pathogens but are sufficiently different so as to be distinguishable from host molecules, and are collectively referred to as pathogen-associated molecular patterns (PAMPs). 8, 9 There are 10 TLRs in the human genome; these are trans-membrane proteins with an extracellular domain having leucine-rich repeats (LRR) and a cytosolic domain called the Toll/IL-1 receptor (TIR) domain. 9 The ligands for these receptors are highly conserved microbial molecules such as lipopolysaccharides (LPS) (recognized by TLR4), lipopeptides (TLR2 in combination with TLR1 or TLR6), flagellin (TLR5), single stranded RNA (TLR7 and TLR8), double stranded RNA (TLR3), CpG motif-containing DNA (recognized by TLR9), and profilin present on uropathogenic bacteria (TLR 11). 10, 11 TLR1, −2, −4, −5, and −6 respond to extracellular stimuli, while TLR3, −7, −8 and −9 respond to intracytoplasmic PAMPs, being associated with the endolysosomal compartment. 9 The activation of TLRs by their cognate ligands leads to production of inflammatory cytokines, and up-regulation of MHC molecules and co-stimulatory signals in antigen-presenting cells as well as activating natural killer (NK) cells (innate immune response), in addition to priming and amplifying T-, and B-cell effector functions (adaptive immune responses). [12] [13] [14] [15] Thus, TLR stimuli serve to link innate and adaptive immunity 13 and can therefore be exploited as powerful adjuvants in eliciting both primary and anamnestic immune responses.
We have recently begun to explore in detail, structure-activity relationships (SAR) of several immunostimulatory chemotypes. [16] [17] [18] [19] [20] [21] [22] [23] [24] Our attention has focused particularly on agonists of TLR2, exemplified by the S- [2,3- 
bis(palmitoyloxy)-(2RS)-propyl]-R-cysteinyl-S-serine
(PAM 2 CS) chemotype, 17, 23 which distinguishes itself from virtually all other TLR agonists in that although the lipopeptide is devoid of any detectable pro-inflammatory activity in ex vivo human blood models (as defined by the production of detectable levels of TNF-α, IL-1β, IL-6, or IL-8), 25 or of local reactogenicity and pyrogenicity in rabbit models, 18 it is potently adjuvantic in murine models of immunization, 25 suggesting that this chemotype may be a safe and effective adjuvant. Extensive SAR on the PAM 2 CS class of compounds 23 led to simplified second-generation mono-acyl lipopeptides in which the spacing between the ester-linked acyl group and the thioether was found to play a crucial role in determining activity; homologation of the ethylene-bridged compound (6d in Scheme 1) by one methylene unit resulted in complete abrogation of activity. 17 The structurally simpler, synthetically more accessible, and water-soluble 6d with its potent TLR2-agonistic properties in both primary screens employing human TLR2, as well as secondary screens in ex vivo human blood models presented an excellent lead. Prior to commencing immunization studies in rodent and non-rodent models, this compound was subjected to further evaluation. We found, entirely to our surprise, that unlike PAM 2 CS, 6d showed exquisite specificity in activating human TLR2 (hTLR2), but not murine TLR2 (mTLR2), suggesting that the binding mode of 6d to TLR2 may be substantially different from that of PAM 2 CS. This conjecture was strengthened by the observation that N-acylation of 6d with a palmitoyl group resulted in complete loss of hTLR2-agonistic activity, which is unexpected given the pronounced activity of the analogous, N-palmitoylated PAM 2 CS compound (PAM 3 CS), and crystallographic evidence for the engagement of the TLR2/TLR1 heterodimer by PAM 3 CS. 26, 27 These preliminary findings warranted a detailed SAR on the monoacylated lipopeptide chemotype, our goals being not only to identify potentially more potent analogues of 6d, but also to attempt to understand the structural correlates determining human versus murine TLR2 specificity.
Results and Discussion
The SAR of the mono-acyl derivatives began with a careful exploration of the nature of the ester-linked acyl group on the mercaptoethanol fragment of the lipopeptide; specifically, we wished to determine the optimal chain length corresponding to maximal TLR2-stimulatory activity, and whether aryl groups could substitute for the palmitoyl group. The syntheses of these analogues were accomplished (Scheme 1) using the strategy previously described by us; 17 as mentioned earlier, 6d, with a palmitoyl group (Scheme 1) was the point of departure. Examination of this series of compounds showed a clear-cut and straightforward SAR: 6d (palmitoyl) and 6e (stearoyl) were active in engaging hTLR2 (3.63 nM and 4.79 nM, respectively, Table 1 ), but entirely inactive in assays using mTLR2 (Fig. 1) . The shorter-chain analogues were completely inactive (Table 1) . Aryl substituents were found to abrogate activity as exemplified by the complete absence of activity in the biphenyl-4-carboxylate (6f) and biphenyl-3-carboxylate (6g), as well as the p-terphenyl-4-carboxylate (6h) derived analogues. The latter results were not unexpected given the dimensions of the hydrophobic tunnel in the crystal structure of TLR2; 26, 28 however, we were also interested in examining the possibility of these inactive analogues behaving as antagonists of TLR2, since there is only one known report of a low-potency lanthionine-derived antagonist. 29 None of the above-mentioned inactive compounds were antagonistic in homotypic (using PAM 2 CS as stimulus) or heterotypic (using lipoteichoic acid [30] [31] [32] as stimulus) assays in mTLR2 and hTLR2 assays (data not shown).
Our previous SAR on the lipopeptides demonstrated the absolute requirement of the esterlinked long-chain group, and of the importance of the orientation of the carbonyl group of the ester; in these earlier studies, we had found that replacement of the long-chain hydrocarbon functional group with polar poly-ether or polyamine moieties were not tolerated. 17 We were interested in examining a more conservative modification. We hypothesized that the replacement of the palmitoyl group by a 2-(ditetradecylamino) acetate fragment (10a, Scheme 2) may confer to the molecule dual hTLR2/mTLR2 activity by mimicking PAM 2 CS. Our assumption was incorrect since both 10a and its mono-alkyl homologue, 10b, were completely inactive (Table 1) .
As mentioned earlier, N-palmitoylation of 6d (11g, Scheme 3) resulted in an unanticipated loss of TLR2-agonistic activity (Table 1) . We therefore examined in detail a variety of alkyl and acyl substituents on the cysteine amine. The N-alkyl derivatives 11a (ethyl), 11b (octyl), and 11c (hexadecyl) analogues (obtained by either reductive amination using appropriate aldehydes for 11a and 11b, or by direct alkylation in the case of 11c using hexadecyl bromide) were inactive (Table 1) . In contradistinction, the short-chain N-acyl analogues were found to be highly active, with a clear dependence on the chain-length: the N-acetyl analogue 11d was found to be the most potent (1 nM), followed by the N-butyryl analogue 11e, and N-octanoyl compound 11f (3.8 nM). Further homologation (11g, palmitoyl) resulted in complete loss of activity. Two points are to be noted; first, the active analogues (11d-11f) retained specificity toward hTLR2 and displayed no agonistic activity in mTLR2; second, while the EC 50 of the lead compound (6d: 3.6 nM) is, at first glance, comparable to that of the N-acetyl derivative (11d: 1 nM), the absolute magnitude of TLR2-induced nuclear translocation of NF-κB is far greater for 11d and approaches that of PAM 2 CS (Fig.  1) , indicating the higher potency of 11d.
The progressive decrease in activity with increasing N-acyl chain length strongly suggested steric issues. We wanted to confirm this hypothesis and also evaluate replacements of the Nacetyl group with functionalities differing in electron-withdrawing properties. The trifluoroacetamido derivative 11h retains weaker activity (EC 50 : 4.5 nM, but low magnitude of NF-κB activation, Fig. 1 ), while the trichloroacetamido analogue 11i is inactive; consistent with these results are the observations that the methanesulfonamide (11j), trifluoromethanesulfonamide (11k) and p-toluenesulfonamide (11l) derivatives are all inactive. Taken together, these results highlight the simultaneous influence of electronic and steric effects of the substituents on the amine.
Given that the cysteine N-acyl substituents showed dramatic differences in activity as described above, it was of interest to explore serine O-acyl substituents as well. The syntheses of these analogues (Scheme 4) were straightforward, requiring the protection of the cysteine amine as the t-butyl carbamate, followed by O-acylation with either anhydride (14a) or acyl chlorides (14b, 14c). The activity of the O-acetyl analogue 14a is virtually indistinguishable from that of 6d; progressive loss in activity was evident with increasing acyl chain lengths ( Fig. 1 and Table 1 ). As was observed for all of the compounds described above, the O-acyl analogues were also found to be specific for hTLR2.
Given that N-acetylation appeared to specifically enhance TLR2-agonistic potency while preserving specificity for human TLR2, it was interest to examine if this modification on an inactive homologue of 6d that we had previously identified 17 would also result in augmented agonistic activity. The propylene-bridged 3-((R)-2-amino-3-((S)-3-hydroxy-1-methoxy-1-oxopropan-2-ylamino)-3-oxopropylthio)propyl palmitate compound 15 was Nacetylated to furnish 16 as depicted in Scheme 5. The N-acetylated derivative was found to be active, albeit much weaker in potency than 11d (Table 1, Fig. 1 ), clearly emphasizing the role of N-acetyl group in determining TLR2-agonistic potency, although the structural basis for this observation remains to be elucidated.
Our continuing SAR studies on the TLR2-agonistic lipopeptide chemotype have led to the identification of new analogues possessing strong TLR2-agonistic activity that is exquisitely human TLR2-specific. It is being increasingly appreciated that significant differences between murine and non-rodent species exist not only in receptor specificity to TLR ligands, but also in the cellular responses to them. As has been observed with TLR4 ligands such as taxol, 33 lipid IVa, and E5531, a synthetic lipid A analogue, 34 recent evidence suggests that significant inter-species differences exist for TLR2 also, as exemplified by variations in specificities for lipopeptide recognition in chimeric TLR constructs. 35 Furthermore, the coupling of these pattern recognition receptors to downstream adaptor molecules also appear to be distinct as shown by disparities in clinical outcomes in humans with IRAK-4 (interleukin-1 receptor-associated kinase 4) deficiency versus the susceptibility to pathogens in knockout mice. 36 We do not yet understand the structural basis for this specificity, which will have to await detailed crystallographic studies.
As discussed above, TLR2 agonists appear unique amongst all other TLR agonists in that although the lipopeptides are devoid of any detectable pro-inflammatory activity in ex vivo human blood models, 25 or of local reactogenicity and pyrogenicity in rabbit models, 18 it is potently adjuvantic in murine models of immunization, 25 suggesting that this chemotype may be a safe and effective adjuvant. The human-specific TLR2-agonistic properties of the monoacyl lipopeptides precludes its evaluation in murine models, and it remains to be examined if non-rodent animal models (including non-human primates) would be suitable surrogates to evaluate the safety and efficacy of these analogues. These studies are currently underway.
Experimental Section Chemistry
All of the solvents and reagents used were obtained commercially and used as such unless noted otherwise. Moisture-or air-sensitive reactions were conducted under nitrogen atmosphere in oven-dried (120 °C) glass apparatus. The solvents were removed under reduced pressure using standard rotary evaporators. Flash column chromatography was carried out using RediSep Rf 'Gold' high performance silica columns on CombiFlash Rf instrument unless otherwise mentioned, while thin-layer chromatography was carried out on silica gel CCM pre-coated aluminum sheets. Purity for all final compounds was confirmed to be greater than 97% by LC-MS using a Zorbax Eclipse Plus 4.6 mm × 150 mm, 5 µm analytical reverse phase C 18 column with H 2 O-isopropanol or H 2 O-CH 3 CN gradients and an Agilent ESI-TOF mass spectrometer (mass accuracy of 3 ppm) operating in the positive ion (or negative ion, as appropriate) acquisition mode.
General procedure for the syntheses of compounds 5a-5g
Synthesis of Compound 5a: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tert-butoxycarbonyl)amino)-3-oxopropyl)thio)ethyl
butyrate-To a solution of compound 4 (100 mg, 0.24 mmol) in anhydrous CH 2 Cl 2 (5 mL), were added triethylamine (49 µL, 0.18 mmol) and 4-dimethylaminopyridine (DMAP, 3.0 mg, 0.024 mmol) and the reaction mixture was stirred at room temperature. After 10 min butyryl chloride (30 µL, 0.28 mmol) was added and the reaction mixture was stirred for further 30 min. The solvent was then removed using vacuum and the residue was purified using column chromatography (5% MeOH/CH 2 Cl 2 ) to obtain the compound 5a (99 mg, 85%). 1 4 Hz, 3H). 13 Compounds 5b, 5c, 5e-5g were synthesized similarly as compound 5a. Compound 5d was synthesized as published earlier. 4.24 (t, J = 6.6 Hz, 2H), 3.82 (dd, J = 9.1, 2.9 Hz, 1H), 3.74 (s, 3H), 3.57 (dd, J = 9.1, 3.2 Hz, 1H), 3 .01 (dd, J = 13.9, 5.5 Hz, 1H), 2.92 (dd, J = 13.9, 6.8 Hz, 1H), 2.83 (dd, J = 12.6, 6.3 Hz, 2H), 2.31 (t, J = 7.6 Hz, 2H), 1.61 (dd, J = 14.7, 7.4 Hz, 2H), 1.45 (s, 9H), 1.31 -1.24 (m, 8H), 1.14 (s, 9H), 0.87 (t, J = 6.9 Hz, 3H). 13 butoxycarbonyl) 
5c: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tertbutoxycarbonyl)amino)-3-oxopropyl)thio)ethyl dodecanoate-(124

5e: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tertbutoxycarbonyl)amino)-3-oxopropyl)thio)ethyl stearate-(142 mg, 87%
5f: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tert-
5g: 2-(((R)-3-(((S)-3-(tert-butoxy)-1-methoxy-1-oxopropan-2-yl)amino)-2-((tertbutoxycarbonyl)amino)-3-oxopropyl)thio)ethyl [1,1'-biphenyl]-3-carboxylate-
General procedure for synthesis of compounds 6a-6g
Synthesis of Compound 6a: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl butyrate-Compound 5a
(49 mg, 0.1 mmol) was dissolved in 2 mL of trifluoroacetic acid and stirred for 30 min, followed by removal of the solvent by purging nitrogen and drying under vacuum to obtain the residue which was further purified using column chromatography to obtain the trifluoroacetate salt of compound 6a in quantitative yield (49 mg). 1 R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl) R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl) S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl) R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl) R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl) 
6b: 2-(((
6c: 2-(((
6e: 2-(((R)-2-amino-3-(((
6f: 2-(((
6g: 2-(((
Synthesis of Compound 6h: 2-(((R)-2-amino-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl [1,1'-biphenyl]-3-carboxylate-
To a solution of p-terphenyl-4-carboxylic acid (33 mg, 0.12 mmol) and compound 4 (100 mg, 0.24 mmol) in anhydrous dimethylformamide (DMF), were added triethylamine (33 µL, 0.24 mmol), DMAP (2.9 mg, 0.024 mmol) and O-benzotriazole-N,N,N',N' -tetramethyluronium hexafluorophosphate (HBTU, 55 mg, 0.144 mmol) and the reaction mixture was stirred at room temperature for 14 h, followed by removal of the solvent under reduced pressure. The crude was then dissolved in ethyl acetate and washed with water. The organic fraction was dried over anhydrous sodium sulfate, filtered, concentrated and purified using column chromatography (5% MeOH/CH 2 Cl 2 ) to obtain the compound 5h. The product obtained was dissolved in 2 mL of trifluoroacetic acid and stirred for 30 min, followed by removal of the solvent by purging nitrogen and drying under vacuum to obtain the residue which was further purified using column chromatography to obtain the trifluoroacetate salt of compound 6h (37 mg, 59%). 1 
Syntheses of methyl 2-(ditetradecylamino)acetate (8a) and methyl 2-((tertbutoxycarbonyl)(tetradecyl)amino)acetate (8b)-To
a solution of glycine methyl ester 7 (1.0 g, 8 mmol) in DMF (5 mL) triethylamine (4.5 mL, 32 mmol) was added, followed by 1-bromotetradecane (3.6 mL, 12 mmol) and the reaction mixture was stirred at room temperature for 18 h. The solvent was evaporated, water (50 mL) was added and the product was extracted in CH 2 Cl 2 (100 mL). The organic layer was dried over sodium sulfate and evaporated to afford a mixture of methyl 2-(tetradecylamino)acetate and methyl 2-(ditetradecylamino)acetate. Di-tert-butyl dicarbonate (1.0 g) was added to the solution of this crude mixture in anhydrous CH 2 Cl 2 (10 mL) followed by triethylamine (0.7 mL, 5.25 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The solvent was removed and the product was column purified to furnish compound 8a (330 mg, 9%) and compound 8b (1.01 g, 33%). Spectroscopic evidence for two conformers for 8b was observed in both 1 H and 13 C NMR. acid (9a)-Compound 8a (275 mg, 0 .57 mmol) was dissolved in tetrahydrofuran (THF, 10 mL) and LiOH (68 mg, 2.85 mmol) in 2 mL of H 2 O was added and the reaction mixture was stirred at room temperature for 18 h. The solvent was evaporated, water added, the pH of the aqueous layer was rendered acidic by the addition of 1N HCl, and the product was extracted in CH 2 Cl 2 . The organic layer was dried over anhydrous sodium sulfate, evaporated, and column purified to afford compound 9a as white solid (250 mg, 93%). 1 H NMR (500 MHz, CDCl 3 ) δ 3.29 (s, 2H), 3.13 (s, 1H),  2.72 -2.46 (m, 4H), 1.47 (m, 4H), 1.19 (m, 44H) , 0.81 (t, J = 6.9 Hz, 6H). 13 
8a-
Synthesis of 2-(ditetradecylamino)acetic
Synthesis of (S)-methyl 2-((R)-2-amino-3-((2-(2-(ditetradecylamino)acetoxy)ethyl) thio)propanamido)-3-hydroxypropanoate (10a)-
To the solution of compound 4 (80 mg, 0.189 mmol) and 9a (177 mg, 0.379 mmol) in dry CH 2 Cl 2 (5 mL) N-methylmorpholine (41 µL, 0.379 mmol) and DMAP (9.0 mg, 0.076 mmol) were added, and the reaction mixture was stirred in an ice bath. After 20 min 1-ethyl-3-(3-dimethylaminopropyl) carbodiimide hydrochloride (EDCI.HCl, 58 mg, 0.379 mmol) was added and the reaction mixture was stirred at room temperature for 18 h. 50 mL of CH 2 Cl 2 was added to the reaction mixture and the organic layer was washed with water, brine, dried over anhydrous sodium sulfate and evaporated. The crude product was further column purified to furnish the ester intermediate N-Boc, O-t Bu protected 10a. The product obtained was dissolved in 4 mL of trifluoroacetic acid and stirred for 30 min, followed by removal of the solvent by purging nitrogen and drying under vacuum to obtain the residue which was further purified using column chromatography to obtain the trifluoroacetate salt of compound 10a in quantitative yield. 1 Compound 10b was synthesized similarly as compound 10a. R)-2-(ethylamino)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl) thio)ethyl palmitate-To a solution of compound 6d (50 mg, 0.081 mmol) in anhydrous CH 2 Cl 2 were added acetaldehyde (3.5 mg, 0.081 mmol), 4 drops of acetic acid and macroporous polystyrenebound cyanoborohydride (73 mg, 0.162 mmol). The reaction mixture was stirred for 2 h and then filtered to remove the solid resin. The filtrate was evaporated under vacuum to obtain the residue, which was purified using column chromatography (4% MeOH/CH 2 Cl 2 ), yielding compound 11a (8 mg, 20%) . 1 Compound 11b was synthesized similarly as compound 11a. R)-2-(hexadecylamino)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl) thio)ethyl palmitate-To a solution of compound 6d (100 mg, 0.162 mmol) in anhydrous DMF, triethylamine (56 µL, 0.405 mmol) was added, followed by 1-bromohexadecane (123 µL, 0.405 mmol). The reaction mixture was stirred at room temperature for 14 h. DMF was evaporated at 50 °C and the crude product obtained was purified using column chromatography to give compound 11c (18 mg, 15%) as white solid. 1 25 (s, 50H) , 0.88 (t, J = 6.7 Hz, 6H). 13 R)-2-acetamido-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl) thio)ethyl palmitate-To a solution of compound 6d (50 mg, 0.081 mmol) in anhydrous CH 2 Cl 2 were added triethylamine (17 µL, 0.121 mmol) and acetic anhydride (8 µL, 0.081 mmol). The reaction mixture was stirred for 2 h. The solvent was removed under vacuum to obtain the residue which was purified using column chromatography (6% MeOH/CH 2 Cl 2 ), furnishing compound 11d (35 mg, 79% Compounds 11h, 11j and 11k were synthesized similarly as compound 11d. R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-3-oxo-2-(2,2,2-trifluoroacetamido) 
10b: (S)-methyl 2-((R)-2-amino-3-((2-(2-(tetradecylamino)acetoxy)ethyl)thio)propanamido)-3-hydroxypropanoate-
Synthesis of Compound 11a: 2-(((
11b: 2-(((R)-3-(((S
)
Synthesis of Compound 11c: 2-(((
Synthesis of Compound 11d: 2-(((
11h: 2-(((
11j: 2-(((R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl)amino)-2-(methylsulfonamido)-3-oxopropyl)thio)ethyl palmitate-(7 mg, 15%
Synthesis of Compound 11e: 2-(((R)-2-butyramido-3-(((S)-3-hydroxy-1-
methoxy-1-oxopropan-2-yl)amino)-3-oxopropyl)thio)ethyl palmitate-To a solution of compound 6d (50 mg, 0.081 mmol) in pyridine (1 mL), butyryl chloride (10.2 µL, 0.097 mmol) was added and the reaction mixture was stirred at room temperature for 1 h. The volatiles were removed by evaporation, and the crude product obtained was purified using column chromatography (10 % MeOH/CH 2 Cl 2 ) to obtain compound 11e as a white solid (35 mg, 76% Compounds 11f and 11g were synthesized similarly as compound 11e. R)-3-(((S)-3-hydroxy-1-methoxy-1-oxopropan-2-yl) The reaction mixture was stirred for 2 h and the solvent was then removed under vacuum. The residue was purified using column chromatography (5% MeOH/ CH 2 Cl 2 ) to obtain compound 11i (6 mg, 12% TLR2-specific NF-κB induction by selected analogues in human and murine TLR2 reporter gene assays. Means and standard deviations of quadruplicate samples are shown.
11f: 2-(((
Synthesis of Compound 11i: 2-(((R)-3-(((S
Synthesis of Compounds 14a: 2-(((R)-3-(((S)-3-acetoxy-1-methoxy-1-oxopropan-2-yl)amino)-2-amino-3-oxopropyl)thio)ethyl palmitate-To
Synthesis of Compound 14b: 2-(((R)-2-amino-3-(((S
